In a blow to patients who currently lack recommended treatment options for chronic heart failure with preserved or mildly reduced ejection fraction, Boehringer Ingelheim and Lilly Alliance’s empagliflozin has not received a positive recommendation from the National Institute for Health and Care Excellence (NICE).
As yet there are no clinically proven medications recommended by NICE for patients with the condition, despite the Medicines and Healthcare products Regulatory Agency (MHRA) approval for empagliflozin – also known as Jardiance – to treat symptomatic chronic heart failure regardless of ejection fraction last year…
